Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17445849 | 0.73 | ITGB3 (0.40) | NPC1 | |
| SCHEMBL17445823 | 0.71 | KDM4E (0.40) | RAB9AKMT2ANPC1CYP3A4POLB | |
| SCHEMBL18910499 | 0.71 | P2RX7 (0.47) | KMT2AL3MBTL1CYP3A4CYP2C19CYP2C9 | |
| SCHEMBL17445833 | 0.69 | KMT2A (0.46) | KMT2APOLB | |
| SCHEMBL17445803 | 0.69 | ALDH1A1 (0.45) | RAB9AKMT2ANPC1CYP3A4CYP2C19 | |
| SCHEMBL926701 | 0.68 | POLB (0.70) | RAB9AKMT2ANPC1POLB | |
| SCHEMBL15894492 | 0.68 | KMT2A (0.52) | RAB9AKMT2ANPC1L3MBTL1POLB | |
| SCHEMBL15877675 | 0.68 | KMT2A (0.52) | RAB9AKMT2ANPC1L3MBTL1POLB | |
| SCHEMBL15877677 | 0.68 | KMT2A (0.52) | RAB9AKMT2ANPC1L3MBTL1POLB | |
| SCHEMBL15877933 | 0.68 | KMT2A (0.51) | RAB9AKMT2ANPC1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10273208-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NORTHWESTERN UNIVERSITY (US) | 2019-04-30 | — | — | US | disclosed |
| US-20170152228-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152228-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2017-06-01 | — | — | US | disclosed |
| US-9586890-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NORTHWESTERN UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586890-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NORTHWESTERN UNIVERSITY (US) | 2017-03-07 | — | — | US | disclosed |
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-01-21 | — | — | US | disclosed |
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NORTHWESTERN UNIVERSITY (US) | 2016-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152228-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NEDD4, STUB1, CUL1 | RAB9A 1779/4885KMT2A 2599/4885NPC1 1703/4885 |
| US-20160016893-A1 | SCREENING METHODS FOR THE BINDING AFFINITY OF CHEMICAL ENTITIES TO BIOLOGICAL MOLECULES AND NEDD4-1 INHIBITORS IDENTIFIED BY THE SCREENING METHODS | NEDD4, STUB1, UBQLN1 | RAB9A 1129/4885KMT2A 3105/4885NPC1 376/4885 |
| US-10273208-B2 | Screening methods for the binding affinity of chemical entities to biological molecules and NEDD4-1 inhibitors identified by the screening methods | NEDD4, STUB1, CUL1 | RAB9A 1779/4885KMT2A 2599/4885NPC1 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.